BRPI0608429A2 - método e kit para prognóstico ou avaliação da eficácia do tratamento de um tumor sólido em um paciente de interesse; e método para a identificação de marcadores que sejam prognósticos de um tumor sólido - Google Patents

método e kit para prognóstico ou avaliação da eficácia do tratamento de um tumor sólido em um paciente de interesse; e método para a identificação de marcadores que sejam prognósticos de um tumor sólido

Info

Publication number
BRPI0608429A2
BRPI0608429A2 BRPI0608429-0A BRPI0608429A BRPI0608429A2 BR PI0608429 A2 BRPI0608429 A2 BR PI0608429A2 BR PI0608429 A BRPI0608429 A BR PI0608429A BR PI0608429 A2 BRPI0608429 A2 BR PI0608429A2
Authority
BR
Brazil
Prior art keywords
solid tumor
patients
treatment
predicting
evaluating
Prior art date
Application number
BRPI0608429-0A
Other languages
English (en)
Inventor
Michael E Burczynski
Frederick Immermann
Andrew Strahs
Donna Slonim
William L Trepicchio
Andrew J Dorner
Natalie C Twine
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0608429A2 publication Critical patent/BRPI0608429A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

MéTODO E KIT PARA PROGNóSTICO OU AVALIAçãO DA EFICáCIA DO TRATAMENTO DE UM TUMOR SóLIDO EM UM PACIENTE DE INTERESSE; E MéTODO PARA A IDENTIFICAçãO DE MARCADORES QUE SEJAM PROGNóSTICOS DE UM TUMOR SóLIDO. A presente invenção apresenta métodos, sistemas e equipamento para o prognóstico ou avaliação do tratamento de tumores sólidos. Marcadores genéticos que sejam prognósticos de tumores sólidos podem ser identificados de acordo coma presente invenção. Cada marcador genético tem padrões de expressão alterados em PBMCs de pacientes com tumores sólidos após o início de um tratamento anticâncer, e as magnitudes dessas alterações estão correlacionadas com os resultados clínicos desses pacientes. Em uma modalidade, usa-se um modelo de riscos proporcionais de Cox para determinar as correlações entre resultados clínicos de pacientes com RCC e alterações na expressão do gene em PBMCs desses pacientes no decorrer de um tratamento com CCI-779. Exemplos não limitativos de genes identificados pelo modelo de Cox são representados nas Tabelas 4A, 4B, 5A e 55. Esses genes podem ser usados como marcadores substitutos para prognóstico de RCC. Também podem ser usados como indicadores farmacogenómicos para a eficácia de CCI-779 ou outros fármacos antícâncer.
BRPI0608429-0A 2005-02-18 2006-02-17 método e kit para prognóstico ou avaliação da eficácia do tratamento de um tumor sólido em um paciente de interesse; e método para a identificação de marcadores que sejam prognósticos de um tumor sólido BRPI0608429A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65408205P 2005-02-18 2005-02-18
PCT/US2006/005772 WO2006089185A2 (en) 2005-02-18 2006-02-17 Pharmacogenomic markers for prognosis of solid tumors

Publications (1)

Publication Number Publication Date
BRPI0608429A2 true BRPI0608429A2 (pt) 2009-12-29

Family

ID=36649050

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608429-0A BRPI0608429A2 (pt) 2005-02-18 2006-02-17 método e kit para prognóstico ou avaliação da eficácia do tratamento de um tumor sólido em um paciente de interesse; e método para a identificação de marcadores que sejam prognósticos de um tumor sólido

Country Status (15)

Country Link
US (1) US20090061423A1 (pt)
EP (1) EP1849007A2 (pt)
JP (1) JP2008529554A (pt)
KR (1) KR20070115891A (pt)
CN (1) CN101120255A (pt)
AU (1) AU2006214078A1 (pt)
BR (1) BRPI0608429A2 (pt)
CA (1) CA2598393A1 (pt)
CR (1) CR9298A (pt)
IL (1) IL185206A0 (pt)
MX (1) MX2007010001A (pt)
NO (1) NO20074065L (pt)
RU (1) RU2007129864A (pt)
WO (1) WO2006089185A2 (pt)
ZA (1) ZA200706919B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5435529B2 (ja) * 2005-09-02 2014-03-05 東レ株式会社 腎ガン診断、腎ガン患者予後予測のための組成物および方法
US20100222230A1 (en) * 2007-04-11 2010-09-02 The General Hospital Corporation Diagnostic and prognostic methods for renal cell carcinoma
NZ600268A (en) * 2010-01-11 2014-08-29 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
AU2015202116B2 (en) * 2010-01-11 2017-06-08 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
MX369911B (es) 2013-05-30 2019-11-26 Genomic Health Inc Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia.
JP6427750B2 (ja) * 2013-10-02 2018-11-28 コニカミノルタ株式会社 Ｃｘｃｌ１、ならびにｓｍｏｘおよび／またはｉｄ１の発現量に基づく肺癌患者の予後を判定するためのデータ収集方法およびキット
WO2016126883A1 (en) * 2015-02-03 2016-08-11 Cedars-Sinai Medical Center Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer
US20180100859A1 (en) * 2015-03-24 2018-04-12 Eutropics Pharmaceuticals, Inc. Surrogate functional biomarker for solid tumor cancer
CN111537424B (zh) * 2020-04-26 2022-10-28 北京市神经外科研究所 基于外周血细胞评估脊髓胶质瘤患者预后性的系统
CN111640518A (zh) * 2020-06-02 2020-09-08 山东大学齐鲁医院 一种宫颈癌术后生存预测方法、系统、设备及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020076735A1 (en) * 1998-09-25 2002-06-20 Williams Lewis T. Diagnostic and therapeutic methods using molecules differentially expressed in cancer cells
JP3944996B2 (ja) * 1998-03-05 2007-07-18 株式会社日立製作所 Ｄｎａプローブアレー
WO2002061144A2 (en) * 2001-01-31 2002-08-08 Whitehead Institute For Biomedical Research Brain tumor diagnosis and outcome prediction
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
CA2505416A1 (en) * 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors

Also Published As

Publication number Publication date
IL185206A0 (en) 2008-01-06
US20090061423A1 (en) 2009-03-05
CA2598393A1 (en) 2006-08-24
CN101120255A (zh) 2008-02-06
WO2006089185A8 (en) 2007-09-27
JP2008529554A (ja) 2008-08-07
ZA200706919B (en) 2008-06-25
WO2006089185A3 (en) 2006-09-28
EP1849007A2 (en) 2007-10-31
KR20070115891A (ko) 2007-12-06
RU2007129864A (ru) 2009-03-27
CR9298A (es) 2007-11-23
MX2007010001A (es) 2007-09-27
WO2006089185A2 (en) 2006-08-24
AU2006214078A1 (en) 2006-08-24
NO20074065L (no) 2007-11-14

Similar Documents

Publication Publication Date Title
Sharma et al. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)
Yan et al. Novel fusion transcripts associate with progressive prostate cancer
Goutham et al. DNA double-strand break analysis by γ-H2AX foci: a useful method for determining the overreactors to radiation-induced acute reactions among head-and-neck cancer patients
NO20074065L (no) Farmakogenomiske markorer for prognose av faste tumorer
BR112012009879A2 (pt) "métodos diagnósticos para determinar o prognóstico de câncer de pulmão de não pequenos células"
Alsbeih et al. Gender bias in individual radiosensitivity and the association with genetic polymorphic variations
BR112015023783A2 (pt) método para diagnóstico e tratamento de metastase no câncer
NI200700126A (es) Metodos y sistemas para el pronostico y tratamiento de tumores solidos
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
BR112014025269A2 (pt) método para o prognóstico e tratamento de metástase de câncer
BRPI0907637A8 (pt) biomarcadores p53
MY183402A (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
AR099856A1 (es) Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
BRPI1013546A2 (pt) usos de um inibidor da timidilato sintase e de uma terapia anticâncer
BR112021016595A2 (pt) Método de diagnóstico ou prognóstico de câncer, métodos para diagnosticar câncer ou para triagem de câncer, para monitorar um indivíduo, para monitorar o tratamento de câncer, para avaliar a resposta de um indivíduo a um tratamento de câncer e para tratar um indivíduo com câncer detectado, kit e uso do kit
Dong et al. Response to first-line chemotherapy in patients with non–small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status
Puente et al. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
ATE553112T1 (de) Ttk in der diagnose und als therapeutisches target bei krebs
Huang et al. Plasma Epstein–Barr Virus DNA Temporal Clearance Pattern During Induction-Concurrent (Chemo) Radiation Therapy for Risk Stratification in Nasopharyngeal Carcinoma
MXPA06014175A (es) Diagnostico o pronostico del curso del cancer de mama.
CY1115258T1 (el) Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων
Wang et al. Association of PTEN gene SNPs rs2299939 with PFS in patients with small cell lung cancer treated with early radiotherapy
WO2006065940A3 (en) Identification and use of prognostic and predictive markers in cancer treatment
Kim et al. Identification of potential molecular biomarkers in response to thioredoxin reductase 1 deficiency under nickel exposure

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.